Previsão

O preço-alvo médio dos analistas é € 29,33 (+23,55%). A mediana é € 31,21 (+31,47%).

Comprar	26
Manter	10
Vender	1

Notícias Ir para o feed de notícias

Acadia Pharmaceuticals: US court preliminarily approves settlement in shareholder derivative suit

A US district court in California gave preliminary approval to the settlement in the shareholder derivative suit Kanner et al. v. Biggar et al. on August 24, 2026. Acadia must publish the court documents notifying shareholders of the settlement; details are available in the exhibits to the SEC filing. Acadia’s operations remain stable, the stock is trading at $27.83, and analyst ratings as well as recent approvals and clinical progress support a positive outlook. » Mais em de.investing.com
Acadia Pharmaceuticals puts growth and remlifanserin pipeline at center of conference

At the Canaccord conference Acadia Pharmaceuticals highlighted strong commercial momentum for NUPLAZID (annualized revenue run rate of $700 million) and DAYBUE, whose STIX formulation is rapidly gaining market share. The company expects Phase II/III data for remlifanserin in Alzheimer’s psychosis in September/October 2024, seen as an important catalyst. Acadia has roughly $1 billion in cash, plans to launch DAYBUE in Europe after a positive CHMP opinion, and remains open to selective acquisitions. Management cited awareness building, commercial discipline and regulatory uncertainty as key factors for further growth. » Mais em de.investing.com
Acadia Pharmaceuticals stock reaches 52-week high after strong Q2 results

Acadia Pharmaceuticals shares rose to a 52-week high of around $29.77 and gained 36% over the past six months (YTD +18.23%). For Q2 2026 the company reported revenue of about $308 million, beating the $296 million consensus, driven by strong Daybue sales ($125 million) and stable Nuplazid revenue. Several analysts then raised their price targets (e.g., RBC USD 37, Oppenheimer USD 25, Citizens USD 36) and H.C. Wainwright reiterated a buy recommendation, citing progress in the phase‑2 RADIANT study. InvestingPro rates the stock as undervalued, and the company raised its 2026 guidance, supporting the positive outlook. » Mais em de.investing.com

Dados financeiros da empresa

No último trimestre, Acadia Pharmaceuticals registou receitas de € 269,84 mi e um ganho líquido de € 27,6 mi

(EUR)	junho de 2026	YoY
Receitas	269,84 mi	20,21%
Ganho bruto	245,03 mi	18,44%
Ganho líquido	27,6 mi	22,00%
EBITDA	28,35 mi	22,55%

Dados fundamentais

Métrica	Valor
Capitalização bolsista	€ 4,13 bi
Número de ações	171,24 mi
Máximo/mínimo de 52 semanas	€ 26,84 - € 17,07
Dividendos	Não
Beta	0,86
PER (PE Ratio)	12,37
PEG (PEG Ratio)	0,18
P/VC (PB Ratio)	3,66
P/V (PS Ratio)	4,19

Perfil da empresa

ACADIA Pharmaceuticals Inc. ist ein biopharmazeutisches Unternehmen, das sich auf die Entwicklung und Vermarktung von niedermolekularen Arzneimitteln konzentriert, die den ungedeckten medizinischen Bedarf bei Erkrankungen des zentralen Nervensystems decken. Das Unternehmen bietet NUPLAZID (Pimavanserin) zur Behandlung von Halluzinationen und Wahnvorstellungen im Zusammenhang mit der Psychose der Parkinson-Krankheit an. Die Pipeline des Unternehmens umfasst Pimavanserin, das sich in Phase 3 der Entwicklung für die Behandlung von Psychosen der Alzheimer-Krankheit und von Negativsymptomen der Schizophrenie befindet; Trofinetide, ein neuartiges synthetisches Analogon, das sich in Phase 3 der Entwicklung für die Behandlung des Rett-Syndroms befindet; ACP-044, ein neuartiges, oral verabreichtes Nicht-Opioid-Analgetikum, das sich in Phase 2 der Entwicklung zur Behandlung von akuten und chronischen Schmerzen befindet; und ACP-319, ein positiver allosterischer Modulator des Muscarinrezeptors, der sich in Phase 1 der Entwicklung zur Behandlung von Schizophrenie und kognitiven Störungen bei Alzheimer befindet. ACADIA Pharmaceuticals Inc. wurde 1993 gegründet und hat seinen Hauptsitz in San Diego, Kalifornien.

Nome	Acadia Pharmaceuticals
CEO	Catherine E. Owen Adams
Sede	San Diego, ca EUA
Site	acadia-pharm.com
Setor	Materiais básicos
Indústria	Produtos químicos
Entrada em bolsa	27/05/2004
Colaboradores	797